|

HS-20093 Clinical Trials

9 actively recruiting trials

Pipeline

Phase 1: 4Phase 2: 4Phase 3: 1

Top Sponsors

  • Hansoh BioMedical R&D Company9

Indications

  • Cancer9
  • Advanced Solid Tumor2
  • Metastatic Colorectal Cancer (CRC)1
  • Advanced Prostate Cancer1
  • Sarcoma1

Other9 trials

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Phase 2
ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors
Phase 2
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase 2
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Phase 3
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Phase 1
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Phase 1
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Phase 1
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Phase 2
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.